Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Mehdi Razavi
AddedMar 31, 2024
UpdatedMay 31, 2026
Mehdi Razavi

Mehdi Razavi

Board Member, Saranas

CrunchbaseLinkedIn

Mehdi Razavi's Career

Saranas
Saranas

Houston, TX, US

Board Member· Board
Maxwell Biomedical
Maxwell Biomedical

San Diego, CA, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Mehdi Razavi's Career

Saranas
Saranas
Series B$29.2M72011Houston, TX, US
Board Member· Board

Leadership at Saranas

Zaffer SyedZaffer SyedCEO

Similar to Saranas

Innovative Trauma CareInnovative Trauma CareSan Antonio, TX, USMedical Devicesest. 2010Innovative Trauma CareSan Antonio, TX, US · est. 2010

Innovative Trauma Care: A medical device company specializing in hemorrhage solutions.

Angel · $12.3M16
HemoraiHemoraiAustin, TX, USMedical Deviceest. 2019HemoraiAustin, TX, US · est. 2019

Hemorai: Pioneering solutions for early detection and prevention of hemorrhagic shock.

Pre-Seed · $170k5
Sanus SolutionsSanus SolutionsAtlanta, GA, USMedical Softwareest. 2017Sanus SolutionsAtlanta, GA, US · est. 2017

Sanus Solutions: AI-powered medical software for real-time monitoring and prevention of surgical infections.

Seed · $20k2
Early Bird MedicalEarly Bird MedicalMalvern, PA, USMedical Devicesest. 2020Early Bird MedicalMalvern, PA, US · est. 2020

Early Bird Medical: Revolutionizing women's health through innovative medical devices.

Series A · $17.2M8
Maxwell Biomedical
Maxwell Biomedical
Seed$8M142019San Diego, CA, US
Co-Founder

Leadership at Maxwell Biomedical

Randy WernethRandy WernethCEO
Aydin BabakhaniAydin BabakhaniBoard Member

Similar to Maxwell Biomedical

MediCool TechnologiesMediCool TechnologiesRochester, MN, USMedical Devicesest. 2015MediCool TechnologiesRochester, MN, US · est. 2015

MediCool Technologies: Painless solutions for preventing and treating cardiac arrhythmias.

Seed · $896k6
Medical Device InnovationsMedical Device InnovationsEscondido, CA, USMedical Devicesest. 2010Medical Device InnovationsEscondido, CA, US · est. 2010

ION Medical develops novel, easy-to-use tech for Atrial Fibrillation & Hypertension treatment, focusing on safety & long-term effectiveness.

Pre-Seed · $701.7k30
Atrility MedicalAtrility MedicalMadison, WI, USMedical Devicesest. 2017Atrility MedicalMadison, WI, US · est. 2017

Cardiac device manufacturer setting new standards in arrhythmia monitoring with AtriAmp.

Series A · $4M9
CardioFocusCardioFocusMarlborough, MA, USMedical Devicesest. 1990CardioFocusMarlborough, MA, US · est. 1990

US-based CardioFocus advances ablation treatments for cardiac disorders through biotechnology.

Public · $268M71

People Similar to Mehdi Razavi

Nugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailJoshua McClureJoshua McClureBoard Member · Maxwell BiosciencesAlireza HassaniAlireza HassaniFounder · MaxwellianLance PooleLance PooleCo-Founder · Maxwell FinancialAdriana Cisneros BasultoAdriana Cisneros BasultoCo-Founder · MaxwellMehdi KargarMehdi KargarCo-Founder · Maxterial